PharmaLytica 2021 Hyderabad review.

Ferring Pharma to set up $250m R&D, manufacturing facility in Hyderabad


Swiss pharma giant Ferring Pharmaceuticals will be investing $250 million in setting up a manufacturing facility and R&D centre in the city’s life sciences hub of Genome Valley. 

The Euro 2billion-turnover specialty biopharmaceutical player plans to complete the project in three phases, with an investment of Rs 235 crore coming in the first phase itself, Telangana industries minister KT Rama Rao’s office said on Saturday after the European giant laid the foundation stone  for the facility. 

This is Ferring’s second manufacturing and R&D facility in India after Maharashtra, where it also has its India commercial operations. Ferring established its Indian subsidiary in 1997. 

Speaking on the occasion, Ferring India CEO Suresh Pattathil said the new facility will add to group’s global R&D capabilities and help build a pool of novel research for emerging healthcare challenges around the world. He also said Ferring’s association with Hyderabad began after the group’s chairman Dr Fredrick Paulsen evinced keen interest in investing in the city on the “back of progressive governance and forward-looking industry policies, and the presence of the right infrastructure, skilled manpower pool for R&D and manufacturing that are conducive to new business investments”. 

Ferring Pharmaceuticals is focused on reproductive medicine and women’s health with a strong presence in specialty areas within gastroenterology and urology. The St Prex, Switzerland, headquartered Ferring has manufacturing facilities across Europe, North America, South America, China and India marketing its products in over 110 countries.




This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More